Editorial. In this issue, McClure and colleagues publish new and important findings on the pharmacological augmentation of cognitive remediation and skills training with guanfacine (1), an alpha2a-adrenergic agonist with some promise to improve cognition in schizophrenia spectrum disorders. In a randomized controlled trial, the effects of adding guanfacine (compared with placebo) to an abbreviated version of cognitive enhancement therapy were evaluated in people with schizotypal personality disorder.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text.